Private research note
Primary-source documents
Loading company analysis...
Loading company analysis...
Eli Lilly is delivering exceptional growth through Mounjaro and Zepbound while expanding its cardiometabolic pipeline and manufacturing capacity.
Keep researching
Merck leans heavily on its oncology franchise Keytruda while building out newer vaccine and animal health businesses ahead of patent expiration.
Amgen is a large biotech with a diversified portfolio spanning inflammation, oncology, and bone health, along with a growing obesity drug candidate.
Thermo Fisher Scientific supplies lab equipment, reagents, and services used broadly across pharmaceutical, biotech, academic, and industrial research.
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
The SEC filing feed did not return a consistent annual series for this metric.
Review the Earnings tab for the expected date and estimates.
FORM 4
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.
Eli Lilly develops and sells medicines across cardiometabolic health, oncology, immunology, and neuroscience. Its most important current products are Mounjaro for diabetes and Zepbound for obesity, both based on tirzepatide.
The business model depends on patent-protected medicines, clinical development, regulatory approvals, manufacturing scale, physician adoption, insurance coverage, and global commercialization. Lilly's current advantage is a leading incretin portfolio, strong clinical data, a broad pipeline, and expanding production capacity.
Second-quarter revenue increased 48% to $22.97 billion. U.S. revenue grew 33%, while revenue outside the U.S. increased 80%.
Mounjaro revenue rose 91% to $9.94 billion and Zepbound revenue rose 46% to $4.93 billion. Together, the two products represented nearly 65% of quarterly revenue, showing both extraordinary demand and meaningful product concentration.
Gross margin improved to 85.8%. Net income increased 25% to $7.10 billion, and diluted EPS reached $7.94. Earnings included $2.78 billion of acquired in-process research and development charges and $703 million of impairment, restructuring, and other special charges.
The business produces substantial cash, but capacity expansion and acquisitions have increased leverage and capital needs.
Near $1,186 per share, Lilly's equity value was roughly $1.1 trillion. The stock traded near 11.5 times the latest quarterly revenue run rate and roughly 37 times annualized first-half diluted EPS.
That valuation is supported by exceptional growth and high margins, but it assumes continued market leadership, successful launches, and a long runway for obesity and diabetes treatment.
Lilly's live panel recalculates trend, EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, and resistance after each completed daily candle. Pharmaceutical stocks can gap on clinical and regulatory news, so risk should be defined before catalysts.
The automated panel estimates fair value gaps, order blocks, structure changes, and nearby liquidity. Large earnings or trial gaps can remain important reference zones. Confirm any setup with price action and volume rather than treating a detected zone as proof of institutional buying.
The most important checkpoints are prescription growth, realized pricing, capacity, Foundayo uptake, clinical data, safety, regulatory approvals, and the updated full-year outlook.
Final view: Lilly earns a bullish 84 because it combines extraordinary revenue growth, high margins, strong cash flow, market-leading medicines, and a deep pipeline. The premium valuation, product concentration, rising debt, manufacturing demands, and clinical risk keep the score from moving higher.
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.
History begins when the upgraded snapshot records each completed trading day. New entries will accumulate automatically.
Recalculated automatically from daily market data. Values are cached for one hour and use the latest completed candle. Smart money zones are algorithmic estimates and should be confirmed on the chart.
Automatically refreshed from Finnhub. Open each source to evaluate how the development affects the thesis.
The company continues to dominate the weight loss market.
Houston will produce Foundayo ingredients, linking manufacturing capacity directly to Lilly's planned global rollout.
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.